ADAM17 and ovarian cancer: When ADAM17 was inhibited in ovarian cancer cell lines using either anti-ADAM17 antibody D1 or GW280264X, the cancer cells were sensitised to cisplatin-induced apoptosis, therefore significantly reducing cell viability [68].